Figure 3

BRAF melanoma cells with MEK mutations are addicted to BRAF inhibition. (a) Melanoma cells infected with wild-type MEK, MEK^Indel55RT, MEK^Q56P, MEK^V60E, MEK^C121S, MEK^G128V, MEK^P124L, MEK^V154L or empty vector controls were maintained under 1 μm vemurafenib and treated with the indicated dosage of vemurafenib. (b) Cells were maintained under 50 nm dabrafenib and treated with the indicated dosage of dabrafenib. (c) Cells were maintained under 1 μm vemurafenib for 2 weeks followed by 7 days of withdrawal, then treated with the indicated dosage of vemurafenib. All experiments were performed in triplicate; representative wells at the escalating doses are shown to the left of the figure legend.